Drugs / Sing2016 M2SR H3N2 influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04785794 | Jun → Nov 2021 | — | FluGen Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sing2016 M2SR H3N2 influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04785794 ↗ |
| Modality | Vaccine | “Sing2016 M2SR H3N2 monovalent influenza vaccine” NCT04785794 ↗ |
| Route | Intranasal | “administered intranasally” NCT04785794 ↗ |